1 min read
Add as a preferred source on GoogleAllogene Targets Year-End 2027 Enrollment in ALPHA3 Study
The company plans a clinical update around midyear, with interim analysis and any unblinding under DSMB oversight.
Allogene Therapeutics, Inc. expects to finish enrollment in its ALPHA3 study by the end of 2027, setting a year-end target while planning a clinical update around midyear.
The company plans for the study’s interim analysis and any unblinding to proceed under DSMB oversight.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.